Assetmark Inc. Boosts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Assetmark Inc. boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 15.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,152 shares of the medical research company's stock after purchasing an additional 1,242 shares during the quarter. Assetmark Inc.'s holdings in Bio-Rad Laboratories were worth $2,229,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. American Century Companies Inc. grew its position in Bio-Rad Laboratories by 6.0% in the 4th quarter. American Century Companies Inc. now owns 5,599 shares of the medical research company's stock worth $1,839,000 after purchasing an additional 315 shares during the period. LPL Financial LLC boosted its stake in shares of Bio-Rad Laboratories by 34.3% during the 4th quarter. LPL Financial LLC now owns 5,195 shares of the medical research company's stock worth $1,707,000 after acquiring an additional 1,326 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Bio-Rad Laboratories by 173.3% during the 4th quarter. Prudential Financial Inc. now owns 5,968 shares of the medical research company's stock valued at $1,961,000 after buying an additional 3,784 shares in the last quarter. Norges Bank purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $41,644,000. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Bio-Rad Laboratories by 0.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 13,118 shares of the medical research company's stock valued at $4,309,000 after buying an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BIO shares. Royal Bank Of Canada lifted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an "outperform" rating in a research note on Friday. Wells Fargo & Company boosted their price target on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a research note on Friday. UBS Group decreased their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Citigroup reduced their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Saturday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $333.50.

Bio-Rad Laboratories Trading Up 17.6%

BIO stock traded up $42.63 during mid-day trading on Friday, reaching $284.58. The company had a trading volume of 1,106,773 shares, compared to its average volume of 273,866. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43. The company has a market capitalization of $7.74 billion, a PE ratio of 24.26 and a beta of 0.90. The firm has a 50 day moving average of $241.19 and a 200 day moving average of $260.40. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.04%. The firm had revenue of $651.60 million during the quarter, compared to analysts' expectations of $614.82 million. During the same quarter in the prior year, the company earned $3.11 EPS. The company's revenue was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.